Skip to main content

Advertisement

Table 1 Demographic and health characteristics of the sample, in aggregate and by exposure to methotrexate

From: Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis

  Total MTX users Non-MTX users P value
N (%) N (%) N (%)
Total N 180 90 (50.0) 90 (50.0)  
Demographics
 Age in years (range 2–17), mean (SD) 11.8 (3.6) 11.3 (3.7) 12.3 (3.5) 0.0572
 Sex     0.7245
  Female 138 (76.7) 68 (75.6) 70 (77.8)  
  Male 42 (23.3) 22 (24.4) 20 (22.2)  
 Race/Ethnicity     0.1277
  White and non-Hispanic 146 (81.1) 69 (76.7) 77 (85.6)  
  Other 34 (18.9) 21 (23.3) 13 (14.4)  
 Parent education level     0.3119
   ≤ High school graduate 48 (26.7) 21 (23.3) 27 (30.0)  
  Any college 132 (73.3) 69 (76.7) 63 (70.0)  
Clinical characteristics
 Disease durationa in years, mean (SD) 7.7 (3.5) 7.4 (3.4) 8.0 (3.6) 0.1853
 Physician Global Assessmentb, mean (SD) 0.9 (1.3) 0.9 (1.3) 1.0 (1.4) 0.7725
 Overall health rating (range 1–10), mean (SD) 8.2 (2.0) 8.2 (2.1) 8.2 (2.0) 0.9036
Current medications reported usingc:
 Non-Biologic DMARD 116 (64.4) 89 (98.9)d 27 (30.0) < 0.0001
 Biologic DMARD 105 (58.3) 52 (57.8) 53 (58.9) 0.8798
 NSAID 93 (51.7) 44 (48.9) 49 (54.4) 0.4558
 Steroid 29 (16.1) 15 (16.7) 14 (15.6) 0.8393
 Herbals or non-vitamin supplement 13 (7.2) 4 (4.4) 9 (10.0) 0.1499
Frequency of routine visits to rheumatologist     0.0787
 Monthly 10 (5.6) 6 (6.7) 4 (4.4)  
 Every 6 to 8 weeks 12 (6.7) 9 (10.0) 3 (3.3)  
 Every 3 months 116 (64.4) 61 (67.8) 55 (61.1)  
 Every 6 months 33 (18.3) 11 (12.2) 22 (24.4)  
 Every 9–12 months 9 (5.0) 3 (3.3) 6 (6.7)  
Satisfaction of child’s medical care     0.1972
 Very satisfied 161 (89.4) 84 (93.3) 77 (85.6)  
 Somewhat satisfied 14 (7.8) 5 (5.6) 9 (10.0)  
 Somewhat or very dissatisfied 5 (2.8) 1 (1.1) 4 (4.4)  
  1. Column percentages are displayed
  2. P-values derived from the chi-squared (χ2) or Wilcoxon tests
  3. MTX methotrexate, DMARDs disease-modifying antirheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs, Steroids included joint injections, oral steroids, intravenous steroids, or steroid eye drops
  4. aDisease duration was calculated by subtracting age of disease onset from age at survey administration date
  5. bPhysician Global Assessment results are reported based on sub-sample of N = 153 participants who had non-missing values for this measure (N = 78 in the MTX users sub-sample). Physician global assessment has an allowable range of 0–10; the range in the study sample presented in Table 1 was 0–6
  6. cMedication ategories are not mutually exclusive, therefore, medications do not sum to 100%
  7. dValue does not equal 100% due to a participant’s discrepancy in self-reporting